Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2001; 37:286-292
© 2001 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Przyklenk, K.
Right arrow Articles by Kloner, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Przyklenk, K.
Right arrow Articles by Kloner, R. A.

Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis

Karin Przyklenk, PhD, FACCa and Robert A. Kloner, MD, PhD, FACCa

a Heart Institute, Good Samaritan Hospital, and Department of Medicine, Section of Cardiology, University of Southern California, Los Angeles, California, USA



View larger version (20K):

[in a new window]
 
Figure 1 Results (group means ± SEM) for Protocol 1: coronary artery stenosis -> stable coronary flow. (A) % Flow-time area and (B) Regional myocardial blood flow (RMBF) in endocardial (Endo) and epicardial (Epi) segments of the stenotic left anterior descending coronary artery bed for control and sildenafil-treated dogs. Black bars indicate controls; white bars indicate sildenafil. PreTreat = data obtained during the initial hour before randomization and treatment.

 


View larger version (19K):

[in a new window]
 
Figure 2 Results (group means ± SEM) for Protocol 2: coronary artery injury + stenosis -> cyclic variations in coronary flow (CFVs). (A) In vitro platelet aggregation (i.e., maximum impedance in response to 10 µg collagen), and (B) % Flow-time area for control and sildenafil-treated dogs. Black bars indicate controls; white bars indicate sildenafil. PreTreat = data obtained during the initial hour before randomization and treatment. * p < 0.05 vs. control; {dagger} p < 0.05 vs. PreTreat.

 


View larger version (46K):

[in a new window]
 
Figure 3 Whole-blood impedance aggregometry: Protocol 3. (A) Original recordings of in vitro platelet aggregation (i.e., increase in impedance) in blood aliquots exogenously treated with sildenafil, the adenosine A2 agonist CGS 21680, sildenafil + CGS 21680, and no drug (control). Arrows indicate addition of collagen (10 µg); bar = 2 min. (B) % Change in impedance (mean ± SEM) seen in CGS 21680-treated aliquots versus paired "no drug" samples. Data were obtained at baseline and after dose 2 in two vehicle-treated and two sildenafil-treated dogs. Black bars indicate controls; white bars indicate sildenafil.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement